Functional monoamine-receptor profiling with ONE-GO biosensors
Cell-based study · HEK293T cells expressing individual GPCRs and cognate ONE-GO G-protein biosensors; 45-receptor panel [1]
Iloperidone inhibited agonist-evoked signaling at dopamine, serotonin and adrenergic receptors, with generally poor agonist efficacy in this panel. The same profiling experiment detected inverse agonism at 5-HT1B and 5-HT1D. This is a functional G-protein readout, not a binding-affinity determination.
| Endpoint | Reported result | Reference |
|---|---|---|
| Agonist-evoked G-protein activation across the receptor panel | Normalized ΔBRET Qualitative antagonism including D2R, D3R, 5-HT2A and α2C-AR; mean, n=3–7 as reported for Figure 5A. | [1] |
| Basal signaling at 5-HT1B and 5-HT1D | Normalized ΔBRET Inverse-agonist responses with iloperidone; qualitative result, no exact potency estimated from the heatmap. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 nM, 10 nM, 100 nM, 1 µM and 10 µM, plus zero-drug condition (Figure 5A log[M] −9 to −5).
- Exposure duration
- Endpoint BRET was recorded every minute for 5 min; methods state that the analyzed time point depended on receptor/G-protein kinetics.
- Method
- Cell-based ONE-GO BRET assay; transient calcium-phosphate transfection.
- Vehicle
- Drug solvent not specified in the selected main-text BRET methods.
- Co-treatment
- Cognate receptor agonist at EC80 in antagonist mode; drug alone in agonist mode. Brexpiprazole and cariprazine were separate comparators, not combination treatments.
- Reported limits
- Receptor-specific agonist concentrations, biosensor assignments and underlying values in SI5 were not retrieved. No exact receptor-specific IC50, Ki or selected analysis minute is supplied.
Methods and source locations
Compound reported in the paper: Iloperidone; Compound label in the paper: Iloperidone
Results apply to the reported iloperidone reagent and assay systems; no supplier or lot equivalence is established.
Figure 5A and caption; Results: Parallel profiling of atypical antipsychotics; STAR Methods: HEK293T BRET measurements and Key Resources Table
Agonist-evoked G-protein activation across the receptor panel: Iloperidone alone or with a cognate agonist at EC80; ΔBRET normalized to the cognate EC80 response. — Figure 5A heatmap and caption; Parallel profiling results; BRET methods, Figure 5A normalization
Basal signaling at 5-HT1B and 5-HT1D: Drug-alone mode of the same panel; responses below the no-agonist baseline. — Figure 5A heatmap; Parallel profiling results